Confirmed germline pathogenic / likely-pathogenic variant in CDH1 (E-cadherin) — Heredita...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-HDGC-CDH1-CONFIRMED-CARRIER |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Diseases | DIS-BREAST DIS-GASTRIC |
| Sources | SRC-ESMO-GASTRIC-2024 SRC-NCCN-BREAST-2025 SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 |
Red Flag Origin
| Definition | Confirmed germline pathogenic / likely-pathogenic variant in CDH1 (E-cadherin) — Hereditary Diffuse Gastric Cancer (HDGC) syndrome. Autosomal-dominant; highly penetrant. Lifetime diffuse-type (signet ring cell) gastric cancer risk ~37-42% by age 80 in females, ~33-37% in males (downward-revised from earlier ~70-80% estimates per IGCLC 2020 + Hansford 2015). Lifetime invasive lobular breast cancer risk in female carriers ~37-55% by age 80 (lobular histology dominant; ductal less). Other low-frequency cancers reported: cleft lip/palate (developmental), signet-ring colon (rare). Linitis plastica presentation common when symptomatic. Patient has confirmed positive germline test; no current personal cancer diagnosis in the carrier being assessed. Prevention-persona RedFlag (§20, v0.3 pediatric predisposition expansion — though HDGC carriers are typically adults not children; included in pedi... |
|---|---|
| Clinical direction | investigate |
| Category | other |
Trigger Logic
{
"any_of": [
{
"finding": "germline_cdh1_pathogenic_variant_confirmed",
"value": true
},
{
"finding": "germline_cdh1_likely_pathogenic_variant",
"value": true
},
{
"finding": "hdgc_igclc_clinical_criteria_met",
"value": true
}
],
"type": "lab_value"
}
Notes
Prevention-persona RedFlag for CDH1 / HDGC confirmed carriers per IGCLC 2020 international guideline. Prophylactic total gastrectomy (PTG) recommended ages 20-30 (range 18-40 per individualised discussion); endoscopic surveillance is acknowledged inferior to PTG (diffuse-type signet-ring cell foci poorly visible) but offered to PTG-declining carriers. Female carriers: BRCA-style breast surveillance from age 30. STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode.
Used By
Indications
IND-HDGC-CDH1-CARRIER-PREVENTION-OBSERVATION- IND-HDGC-CDH1-CARRIER-PREVENTION-OBSERVATIONIND-HDGC-CDH1-CARRIER-PREVENTION-SURVEILLANCE- IND-HDGC-CDH1-CARRIER-PREVENTION-SURVEILLANCE